1. China Stocks

  2. •

    Retail trade

  3. •

    Drugstore chains
Universal Health International Group Holding Ltd.

Universal Health International Group Holding Ltd.

HHKEX:2211
0.41
HKD
0.00
(0.00%)
101.21MMarket Cap
Universal Health International Group Holding Ltd.
HKEX:2211
(Hong Kong Exchange)

Recent

price

0.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2018
2019
2020
2021
2022
2023
2024
TTM
CNY
145.39
205.05
219.01
242.33
150.66
- -
78.27
39.17
30.68
28.96
22.24
16.29
- -
Revenue per Share
13.36
21.91
23.77
1.57
-3.92
- -
-8.58
-12.75
-17.48
-4.27
-1.81
0.01
- -
Basic EPS, GAAP
8.93
21.25
26.33
1.94
-4.32
- -
-10.09
-13.07
-2.84
-0.97
-0.31
-1.52
- -
Free Cash Flow per Basic Share
- -
5.29
2.22
3.78
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
27.44
117.74
129.91
129.43
112.86
0.63
48.22
32.2
14.88
7.34
4.71
4.4
4.24
Book Value per Share
9.71
95.56
89.74
95.64
91.29
0.63
47.67
32.05
14.75
7.25
4.64
4.34
4.24
Tangible Book Value per Share
16
16
20
20
22
36
31
39
39
44
58
67
97
Basic Weighted Avg Shares
2,326
3,323
4,356
4,806
3,379
- -
2,424
1,510
1,185
1,274
1,297
1,089
- -
Sales/Revenue/Turnover
13.59
15.68
15.52
4.3
1.71
- -
-12.12
-32.99
-37.41
-13.29
-6.63
-2.59
- -
Operating Margin (%)
14
27
37
44
47
- -
24
44
109
26
16
14
- -
Depreciation Expense
214
355
473
31
-88
- -
-266
-491
-675
-188
-105
- -
- -
Net Income, GAAP
25.67
25.93
26.21
68.3
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
9.19
10.68
10.85
0.65
-2.6
- -
-10.96
-32.54
-56.99
-14.73
-8.13
0.04
- -
Profit Margin (%)
236
1,941
1,731
1,859
1,734
- -
1,018
434
104
24
-31
-4
39
Working Capital
- -
- -
- -
- -
- -
- -
- -
4
- -
40
40
40
- -
LT Debt
628
2,456
2,625
2,618
2,733
1,937
1,734
1,245
576
409
315
353
340
Total Equity
- -
24.33
18.19
1.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
21.09
16.6
1.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
24.46
19.09
1.2
-3.32
- -
-14.57
-33.05
-74.27
-38.17
-29.16
0.12
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'24
Dec'25
ST Debt
40
30
22
LT Borrowings
- -
40
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
80
80
Market Capitalization
45
41
95

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'24
Dec'25
Total Current Assets
345
296
305
Cash, Cash Equivalents & STI
35
36
51
Accounts Receivable, Net
83
85
69
Inventories
144
123
106
Total Current Liabilities
430
300
266
Payables & Accruals
- -
- -
- -
ST Debt
40
30
22
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-15.04%
-24.36%
12.12%
Free Cash Flow
- -
64.66%
458.71%
Net Income, GAAP
- -
-18.8%
-100.39%
Sales/Revenue/Turnover
- -
-13.19%
-16.04%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,297
2024
- -
- -
1,089
2025
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.81
2024
- -
- -
0.01
2025
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
CVS Health Corporation (NYSE:CVS)
MatsukiyoCocokara & Co. (TSE:3088)
TSURUHA Holdings, Inc. (TSE:3391)
Guardian Pharmacy Services, Inc. (NYSE:GRDN)
MedPlus Health Services Ltd. (NSE:MEDPLUS)
Raia Drogasil S.A. (B3:RADL3)
Business
Universal Health International Group Holding Limited is an investment holding company principally engaged in the distribution and retail of drugs and other pharmaceutical products in the northeastern region of the People's Republic of China. The company operates through three main segments: retail business, involving the retail sale of drugs and pharmaceutical products through drug retail chains; distribution business, focusing on the wholesale distribution of drugs and pharmaceutical products to hospitals, clinics, and other retailers; and others, primarily comprising investments in related companies. Its extensive product portfolio encompasses Chinese patent medicines; chemical preparations; antibiotics and biochemical drugs; traditional Chinese medicine decoction pieces; biological products; protein assimilation preparations; peptide hormones; disinfection products; blood products; medical equipment; prepackaged food; health care products; nutritional food; stereotyped packaging cosmetics; daily necessities; family planning supplies, such as contraceptives and utensils; and dairy products, including infant formula milk powder; while it also provides storage services for pharmaceuticals. Founded in 1998 and headquartered at No. 14-1, Bei Yi Zhong Road, Tiexi District, Shenyang, China, the company primarily serves the domestic Chinese market with approximately 842 employees. In recent developments, Universal Health International Group Holding Limited proposes amendments to its articles of association to modernize governance, enabling electronic communications, hybrid meetings, electronic payments, and treasury share management in line with updated Listing Rules and Cayman Islands laws, subject to shareholder approval at the upcoming annual general meeting; additionally, it reports fiscal year 2025 results with revenue of RMB711.5 million, reflecting a 34.7% year-on-year decline amid a shift to a net loss of RMB26.06 million attributable to shareholders.